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In the case-controlled First Acute Myocardial Infarction (FAMI) study that looked at the inflammatory mechanisms of STEMI in an enrolled sample of 887 patients and 887 matched controls in Italy, Scotland, and China, 13 we observed a 4-fold increase in IL-6 levels in STEMI patients (5.1 [interquartile range, 2.9-9.9] pg/mL) compared with controls (1.4 [0.7-2.7] pg/mL; P<0.0001). Within the first 6 hours from symptom onset, IL-6 levels did not correlate with ischemic time (defined as the time from onset of the symptoms to blood sampling). 13 In this initial period, there was no correlation between IL-6 and CRP or between IL-6 and troponin I (TnI), a myocardial damage marker. 13 Approximately 20% of STEMI patients had IL-6 values >10 pg/mL; this trend was similar across the 3 ethnic groups included in the study. An even larger fraction of patients with STEMI had levels of IL-6 similar to those of controls (≈1.5 pg/mL).
In this study, we tested the hypothesis that IL-6 elevation reveals a selective imbalance among cytokines contributing to the development of STEMI. Alternatively, elevated IL-6 is part of a diverse response to myocardial injury, with potential implications for outcomes. 6, 14 We compared patients in the top IL-6 level, denoted as IL-6 + STEMI, with those in the bottom IL-6 level, called − STEMI, and the controls from the FAMI cohort by measuring 18 cytokines in blood samples obtained before reperfusion and within 6 hours from symptom onset in patients without history of cardiovascular events. 13 We further assessed whether identifiable functional modules 15, 16 (which represent small combined components of cooperating and interacting cytokines) allow us to elucidate some aspects of the disease mechanism. In our investigation, we used dimension reduction and clustering analysis algorithms 17 to disentangle the functional modules from cytokine expression levels and to detect cohorts of cytokines with similar expression profiles (a pattern) in all subjects. 16 A functional module reveals information derived from the common activity of multiple cytokines involved in different but specific pathways, rather than information from a single cytokine. At the same time, we performed statistical analyses on the functional modules, as well as on the single cytokines, with the aim of distinguishing their functions and of clarifying their contributions to diverse clinical outcomes.
In this study, we show the complex and nonlinear relationships among proximal (IL-6) and distal (CRP) proinflammatory mediators, anti-inflammatory mediators (IL-10), and chemokines (such as monokine induced by interferon [IFN]-γ [MIG] ) in the early phases of atherothrombotic events. We observed that IL-6 + STEMI patients are at increased risk of death by identifying single cytokines that can predict this risk, and we defined combined cytokine index that improves the prediction of fatal outcomes. These observations allowed us to characterize 2 STEMI phenotypes, IL-6 + IL-10 + STEMI and IL-6 − IL-10 + STEMI, featuring distinct cytokine patterns and differing outcomes.
Methods

Study Populations
The international multiethnic case-controlled FAMI study, focusing on the inflammatory mechanisms of STEMI, enrolled 887 patients and 887 matched controls from the urban areas of 3 countries (China, Italy, and Scotland), with marked differences in coronary event rates between October 2002 and April 2007 (further details and a list of the 32 enrolling centers are included in the Online Data Supplement). 13 Patients without previous diagnoses of coronary artery disease or history of exertional chest pain were eligible if they had electrocardiographic evidence of ST segment elevation and referred symptom onset within 6 hours. Controls were age-matched, ethnicity-matched, and sex-matched volunteers (78% community-based, 18% hospitalbased, and 4% from undocumented sources). The FAMI study was approved by regulatory and ethics committees in all the participating centers. The study was conducted according to the Helsinki Declaration and the Good Clinical Practice standards. All participants provided written informed consent before enrollment in the study. A 6-month follow-up vital status assessment was performed for enrolled patients. The echocardiographic estimates of left ventricular (LV) ejection fraction of 113 (55%) patients at discharge also were available.
Furthermore, we studied a second Italian cohort of 70 STEMI patients and 125 controls enrolled after informed written consent at San Raffaele Scientific Institute and Centro Cardiologico Monzino from December 2009 to December 2010 (Online Table I for shows patient characteristics). We additionally considered a third independent cohort of 207 STEMI patients enrolled at the Danderyd Hospital, Karolinska Institutet in Stockholm, Sweden, for further validation (Online Table  II shows patient characteristics). 18 A median follow-up of 3.3±1.3 years for the assessment of vital status and reinfarction was available for all 207 cases (details are provided in the Online Data Supplement).
Study Design
We compared patients in the top IL-6 level, denoted as IL-6 + STEMI, with those in the bottom IL-6 level, called IL-6 − STEMI, and the controls from the FAMI cohort. Cases and controls were randomly extracted (with the exception of IL-6 levels and ethnicity) from the FAMI population: 109 cases belonging to the IL-6 + STEMI group were extracted from among the FAMI patients with IL-6 levels >7.6 pg/mL (ie, the 70th percentile of the FAMI population), and 96 cases belonging to the IL-6 − STEMI group were extracted from among the FAMI patients with IL-6 levels <3.2 pg/mL (ie, the 30th percentile of the FAMI population). The 7.6 pg/mL cut-off was chosen because 95% of the entire cohort of FAMI controls had IL-6 levels <7.6 pg/mL. The control group was obtained by extracting (at random) 103 individuals from the FAMI control population. A balanced study containing 100 patients per group has >90% power at the 0.05 significance level to detect differences at approximately 0.5% of the variability in the quantity undergoing study. IL-6 levels in the control group were similar to serum IL-6 levels reported in healthy subjects in previous studies. 6 Similarly, using the Swedish STEMI data, we compared all patients in the top IL-6 level (defined as IL-6 + STEMI; n=62, ≥70th percentile of the 207 Swedish cases of STEMI with a plasmatic IL-6 level ≥2.36 pg/mL) with those in the bottom IL-6 level (called IL-6 − STEMI; n=62, ≤30th percentile of the 207 Swedish cases of STEMI with a plasmatic IL-6 level ≤1.15 pg/mL).
Collection, Storage, and Analysis of Blood Serum
Details are provided in the Online Data Supplement.
Cytokine Analysis
To assess the concentrations of multiple cytokines in our samples, we used the Cytometric Bead Array FLEX SET technology (BD Biosciences) that allowed us to measure analytes per sample simultaneously in a serum volume of 25 μL. We measured analytes with distinct functions, such as proinflammatory and anti-inflammatory cytokines, angiogenic and growth factors, and chemokines. We assessed the concentrations of the following 18 molecules: IL-1β, IL-2, IL-4, IL-7, IL-10, IL-12p70, IFN-γ, tumor necrosis factor-α, Fas-ligand, granulocyte-macrophage colony-stimulating factor, vascular endothelial growth factor, IL-8 (chemokine [C-X-C motif] ligand 8), IFN-inducible protein 10 (chemokine [C-X-C motif] ligand 10), monocyte chemoattractant protein-1 (MCP1/chemokine [C-C motif] ligand 2), MIG (chemokine [C-X-C motif] ligand 9), macrophage inflammatory protein-1α (MIP1α/chemokine [C-C motif] ligand 3), MIP1β (chemokine [C-C motif] ligand 4), and eotaxin (chemokine [C-C motif] ligand 11). In 6 of the 18 analytes measured, more than half of the specimens in each group fell below the lower detection limit of the analytes. Thus, the following molecules were, excluded from further analysis: IL-1β (limit of, 2.3 pg/mL), IL-2 (11.2 pg/mL), IL-4 (1.4 pg/mL), IL-12p70 (0.6 pg/mL), IFN-γ (0.8 pg/mL), and tumor necrosis factor-α (1.2 pg/mL). A description of the Cytometric Bead Array FLEX SET technology is included in the Online Data Supplement and in Online  Figures I and II and Online Tables III and IV .
Statistical Analysis
The statistical analyses provided evidence of significant differences in the clinical, laboratory, and diagnostic characteristics of IL-6 − STEMI and IL-6 + STEMI patients (Tables 1 and 2 and Online  Tables I and II (34) 20 (25) 3, n (%) 16 (22) 26 (33) Medical treatment before sampling Aspirin n (%) 0 (0) 13 (13) 22 (20) 0.28
in the same factor category was significantly different between the IL-6 + STEMI and IL-6 − STEMI groups. We performed a Fisher exact test for each qualitative multivariate factor to check whether the counts of the various factor categories were significantly different in the IL-6 + STEMI and IL-6 − STEMI groups. The first aim of our computational investigation was to detect whether cohorts of cytokines clustered together to form candidate functional modules. The results of this analysis are displayed in Figure 1 (please refer to the Machine Learning [ML] Computational Analysis section). The subsequent aim was to test whether the functional modules yielded statistically stronger results than the single cytokines in discriminating between IL-6 + STEMI and IL-6 − STEMI patients (a comparison with the controls was used as a reference). The results are shown in Figure 2 . We ran a Mann-Whitney nonparametric test for the comparisons. According to the Benjamini-Hochberg correction, 19 the data did not need any adjustment for multiple hypothesis testing. However, to prevent any bias because of multiple hypothesis testing, we adopted a conservative strategy and considered a significant P value threshold of 0.01. In addition, we also performed a Kruskal-Wallis test in which all measured variables in the 3 groups and the respective functional modules (D1 and D2) attained a P<0.01.
To investigate differential LV systolic function at discharge between the IL-6 + IL-10 + and IL-6 + IL-10 − groups-these groups emerged in the previous investigation displayed in Figure 2 -we used a Fisher exact test, the results of which are reported in Figure 3A . In addition, the 6-month outcomes in IL-6 + IL-10 + and IL-6 − IL-10 + patients are compared in Figure 3B , in which the mortality rates were calculated and plotted according to Kaplan-Meier methods, and the comparison between the 2 groups was performed using a log-rank test.
Finally, the receiver-operating characteristic curves displayed in Figure 4 were constructed-and the area under the receiver-operating characteristic curves (area under the curve [AUC]) was evaluated-to assess and compare the predictive ability of the variables (ie, cytokines) and functional modules (D1 and D2) to identify patients at risk for unfavorable outcomes during follow-up (ie, death or myocardial damage). An asymptotic P<0.01 was considered as significant. Statistical analyses were performed with SPSS Statistics 17.0 software.
ML Computational Analysis
ML is a branch of artificial intelligence concerned with the development of algorithms designed to learn rules and parameter settings or to unsupervisedly extract latent information. 17 In this study, we tried to detect patterns hidden in the high-dimensional data set composed of multiple soluble signal values. Our intention was to detect and define separate groups (clusters) of soluble signals that showed concordant levels across patients.
In the analysis, each patient was characterized by a vector of soluble signal values called features according to ML terminology. Each feature reports the level of detected protein in the patient's blood. Each vector comprised the following features: IL-10, IL-8, MCP1, MIG, MIP1α, MIP1β, and CRP. IL-6 was considered to be a label and not a feature in the vector characterizing each patient, and thus it was never used in the unsupervised ML analysis based on clustering. This analysis did not yield significant differences when CRP was either included or excluded as a feature in the vector (data not shown). The ML analysis was designed to address the questions of: (1) whether it is possible to unsupervisedly recognize any functional module composed of a cohort of cytokines that show a similar expression profile in all the Revascularization after sampling § PCI, n (%) 37 (39) 42 (40) 0.79 Thrombolysis, n (%)
47 (50) 55 (52) No therapy, n (%) 10 (11) 8 (8) ACE indicates angiotensin-converting enzyme; CRP, C-reactive protein; HDL, high-density lipoprotein; IL, interleukin; IQR, interquartile range; LDL, low-density lipoprotein; PCI, percutaneous coronary intervention; Q, quartile; SD, standard deviation; STEMI, ST-elevation acute myocardial infarction.
*P refers to the comparison between IL-6 + STEMI and IL-6 − STEMI patients. †Risk factors: Family history was considered positive if a first-degree relatives (parents, siblings) under the age of 55 for men and under the age of 60 for women, had a myocardial infarction. Hypertension and dyslipidemia and mellitus diabetes were self-reported. Current smoking was considered positive as individuals who currently smoke any tobacco or have quit smoking less than one year ago. Former smokers were defined as individuals who have quit smoking more than a year earlier. The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. Sedentary was defined as a subject who did less than four hours of physical activity a week. ‡Time from blood sampling to blood processing (in minutes) was the time from the blood sampling and the centrifugation of the sample. It is the time in which the blood coagulated.
§Patients with STEMI that were eligible for primary revascularization could be not candidate to this treatment for different issues (ie, contraindication, assurance issues). The final decision for the modality of treatment was upon the single center.
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+ IL-10 + and IL-6 − IL-10 + STEMI 1341 patients; 15, 16 and (2) whether there is any advantage in considering features not as the measures of single cytokines but rather as the summed activity of a module. To answer these questions, we performed: (1) data preprocessing (variance stabilization using log10) 20, 21 ; (2) This modeling strategy is called functional module approach, and in our application we defined the module activity as the average of all cytokine values in the module. 15, 16 Functional modules can be interpreted, from a systems biology point of view, as single logic modules (composed of small cohorts of proteins) that, while embedded in a large network of proteins, have a specific biological function. 15, 16 Each biological function separately contributes to the general program (in our case, a biological pathway) running on the protein network. Their roles can be compared with that of collections of transistors in an electronic circuit or with the different components inside an informational network. Clustering analysis of the cytokine levels allows us to reveal the presence of functional modules. 17 However, statistical hypothesis testing performed on the entire module or on the specific cytokines (which define the module) allows us to reverse-engineer 17 the function of the single cytokines within a module and to discover their possible contributions in different modules or programs (inflammatory pathways related to some clinical outcomes).
Results
Characteristics of the Patients
Most of patients' characteristics, including sex, ethnicity, risk factors, recent clinical history, site of myocardial infarction, number of diseased vessels, ischemic time, TnI levels, and medications before sampling, were not statistically different between the IL-6 + and IL-6 − STEMI groups. These characteristics did not account for the differences in IL-6 levels measured within 3 hours of the onset of symptoms of STEMI (Table 1) , which were 9-times higher in IL-6 + STEMI patients than in IL-6 − STEMI patients. Patients with IL-6 + STEMI were older, had lower high-density lipoprotein cholesterol levels, and had higher CRP levels. To explore this difference in terms of IL-6 response, we analyzed the behavior of multiple cytokines in the groups of STEMI patients and then compared IL-6 + and IL-6 − STEMI versus controls to verify whether other cytokines or patterns of cytokines contributed to the distinction between IL-6 − STEMI patients and controls.
Identification of Cooperating and Interacting Cytokines (Functional Modules) in IL-6 + STEMI Patients
We simultaneously measured levels of the following analytes with distinct functions: IL-1β, IL-2, IL-4, IL-7, IL-10, IL-12p70, IFN-γ, tumor necrosis factor-α, Fas ligand, granulocyte-macrophage colony-stimulating factor, vascular endothelial growth factor, IL-8, inducible protein 10, MCP1, MIG, MCP1α, MIP1β, and eotaxin in IL-6 + STEMI patients, IL-6 − STEMI patients, and controls ( Table 2) . Six of these cytokines were barely detectable in all groups. Therefore, in our subsequent analysis, we considered only the behavior of the signals that were augmented by at least P<0.05 in IL-6 + STEMI patients compared with IL-6 − STEMI patients. They included IL-10, IL-8, MCP1, MIG, MCP1α, MCP1β, and CRP.
The cytokine relations were represented in 2-dimensional reduced space by linear dimensional reduction using principal 
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+ IL-10 + and IL-6 − IL-10 + STEMI 1343 component analysis. By applying the minimum curvilinear affinity propagation clustering analysis algorithm 17 in the space of the first 2 components obtained by principal component analysis, we identified 2 functional modules: one comprising IL-10, IL-8, MCP1α, and CRP (referred to as D1) and the other comprising MCP1, MIG, and MCP1β (referred to as D2 in Figure 1A ). Therefore, each functional module was composed of a cohort of cytokines with a similar expression profile in all patients, and the module activity was defined as the average of the cytokine values in the module. 15, 16 We further assessed the possibility of differentiating the patients on the basis of these 2 functional modules. Figure 1B presents a heat-map graph indicating the distribution of signals within the 2 groups of patients: individual cytokines, the 2 functional modules (D1 and D2), and TnI. This visualization allows for comparison of multiple signals in each patient. The pattern of cytokine increase was not uniform among individual patients and was independent of the extent of necrosis, as revealed by TnI levels. We observed that IL-6 + STEMI patients had a multifaceted inflammatory component in comparison with IL-6 − STEMI patients. Our cytokine modules (D1 and D2) should be able to denoise part of this inhomogeneous inflammatory response in IL-6 + STEMI patients. This was confirmed by Mann-Whitney nonparametric test that evaluated the efficacy of the 2 cytokine modules in discriminating IL-6 + from IL-6 − STEMI patients (Figure 2A ). The modules were by far more effective than individual cytokines in differentiating IL-6
+ from IL-6 − STEMI patients, confirming efficiency in filtering and denoising 22 the original cytokine signals. The modules offer a robust and collective behavior related more closely with IL-6 concentration. We found that IL-10 was the best signal to discriminate between the 2 patient groups. For this reason, we further defined IL-6 + STEMI as IL-6 + IL-10 + STEMI patients. This analysis confirmed that TnI was unable to discriminate between the 2 STEMI groups (Figure 2A , last bin in the histogram, displayed in black). In addition, we demonstrated that among IL-6 + STEMI patients, the discriminatory ability of the functional modules was independent of the extent of myocardial damage and patient age (Online Data Supplement).
Functional Modules and Cytokines in IL-6 + and IL-6 − STEMI Versus Controls
We further assessed whether the functional modules discriminated the IL-6 + and IL-6 − STEMI patients from the controls ( Figure 2B-2C ). IL-6 + STEMI patients differed from the controls on 5 single signals (IL-10, IL-8, CRP, MCP1β, and MIG) and on the D1 and D2 functional modules. IL-10 was the only factor significantly higher in IL-6 − STEMI patients than in controls ( Figure 2B) . Thus, the functional modules and most cytokines that were able to discriminate IL-6
+ from IL-6 − STEMI retained their ability to distinguish IL-6 + IL-10 + STEMI patients from controls. Conversely, we found that IL-6 − STEMI patients and controls had similar cytokine profiles, including IL-6 levels, with the exception of IL-10 ( Figure 2C ). The D1 and D2 functional modules failed to discriminate IL-6 − STEMI patients from controls. Thus, we further defined IL-6 − STEMI patients with a very low grade of systemic inflammation but with a significant increase in IL-10 levels as IL-6 − IL-10 + STEMI patients. We further confirmed these results in a second independent patient cohort in which we again concluded that: (1) IL-6 + STEMI had increased IL-10 levels in comparison with the controls; and (2) IL-6 − STEMI had IL-6 levels similar to those of the controls but with significantly increased IL-10 levels (Online Data Supplement and Online Figure II Figure 3A) . We report the Kaplan-Meier curves of fatal events (0% in the IL-6 − IL-10 + STEMI group vs 11% in the IL-6 + IL-10 + STEMI group) that were significantly different (log-rank P=0.001; Figure 3B ).
To confirm that the prognosis for IL-6 + STEMI patients differed from that for IL-6 − STEMI patients, we validated the results with an independent STEMI population of patients from Sweden. Among 207 patients in that group, we compared the outcomes of IL-6 + STEMI (n=62) versus IL-6 − STEMI (n=62) patients. In the IL-6 + STEMI patients, we observed an increase in the prevalence of death (10/62 and 16.1% vs 3/62 and 4.8%; P=0.07) and reinfarction and death (15/62 and 24.2% vs 6/62 and 9.7%; P=0.05), supporting previous observations (Online Figure IIIA) . Using receiver-operating characteristic curves, we assessed the ability of IL-6 levels at admission to predict fatal events or the composite outcome of reinfarction plus death in a mid-term to long-term follow-up. We found that IL-6 provided significant predictive value both for death (AUC, 0.68; P=0.04) and for the composite of reinfarction and death (AUC, 0.68; P=0.01; Online Figure IIIB and IIIC) , whereas creatine kinase-MB did not (data not shown). It should be noted that IL-6 levels and CRP levels at 48 hours after the onset of STEMI were not predictive of death or for the composite of reinfarction and death, suggesting that the early inflammatory process associated with STEMI potentially can distinguish different patterns of STEMI with different prognoses, whereas the late inflammatory response, mostly secondary to the extent of the myocardial damage, cannot distinguish different patterns of STEMI (Online Figure IIIB and IIIC) .
Furthermore, we used receiver-operating characteristic curves to assess the ability of single cytokines, functional modules (D1 and D2), and combined cytokines to predict death ( Figure 4A-4C) , and we present the respective AUCs to allow a quantitative comparison of the predictions (Figure 4D-4F) . The D1 module (AUC, 0.70; P=0.019) provided significant predictive value compared with the other single cytokines, except for IL-10, which had better predictive value (AUC, 0.76; P=0.002). The D2 module offered significant predictive value (AUC, 0.73; P=0.008) compared with the other single cytokines, except for MIG, which provided similar predictive value (AUC, 0.73; P=0.007).
IL-10 and MIG were the only cytokines that passed the filter test provided by the functional module approach, because they were found to be at least as predictive as their module of origin. For this reason, we proposed a combined cytokine index called the Ammirati-Cannistraci index (AC index) obtained as the average of IL-10 and MIG (derived from D1 and D2, respectively) and IL-6. In the first 6 hours from the onset of STEMI (during which time TnI was not predictive), the AC index yielded the highest predictive value (AUC, 0.86; P<0.0001), which is a significant absolute improvement (+6%) in comparison with IL-6 alone (AUC, 0.80; P<0.0001). The extent of this result is clearer if we consider that an improvement of 6% from AUC 0.5 to AUC 0.56 is not as significant as an improvement of 6% from AUC 0.80 to AUC 0.86. This is more evident if we quantify the improvement in terms of the distance from the exact predictor, which by definition has an AUC of 1. In the first case, we have a relative improvement of 12% (obtained from 100×[0.56-0.5]/[1-0.5]), whereas in the second case we have a relative improvement of 30% (obtained from 100×[0.86-0.8]/[1-0.8]). In fact, this difference in the estimation of the same predictive improvement reflects an intuitive concept: obtaining an improvement when far from the maximal performance is easy compared with obtaining the same improvement when near to the maximal performance.
In conclusion, these findings suggest that IL-6 We observed a similar trend by comparing the predictive performance of the same variables with regard to LV impairment at discharge. Once again, the AC index remained the best predictor (0.70, AUC; P=0.002) and the only one passing the stringent significance threshold (P<0.01) compared with known clinical and laboratory variables, such as age (AUC, 0.61; P=0.06), creatinine level (AUC, 0.50; P=0.93), heart rate (AUC, 0.50; P=0.90), and systolic blood pressure (AUC, 0.53; P=0.65). Given the fact that in this second test IL-6 suffered a decrease in predictive power (AUC, 0.61; P=0.07) and showed only a trend for association with reduced LV ejection fraction (<50%, which is related to myocardial damage), the performance attained by the AC index constitutes: (1) a confirmation of robustness, indicating that the AC index might play a promising role in future practical applications, such as evaluation of patients' prognoses; and (2) additional evidence to suggest that although IL-6 seems strongly and directly related to mortality, the AC index-and the other cytokines considered in its formulations-might account for a wider spectrum of factors that relate also to general myocardial damage.
Discussion
Relatively few studies aiming to determine whether combined signals contribute to shaping the inflammatory response have assessed the reciprocal relationships among cytokines in patients with inflammatory cardiovascular manifestations. 8, 23 In this work, the measurement of several cytokines and the subsequent clustering analysis offer an informative picture of inflammation during the first hours after STEMI onset. October 26, 2012
We identified 2 STEMI patient groups. The first was IL-6 + IL-10 + patients, characterized by high concentrations of IL-6 and selective activation of other cytokines, including a counterbalancing increase in the anti-inflammatory IL-10 cytokine and by a poor midterm prognosis. The second group was IL-6 − IL-10 + patients with low levels of IL-6, a lack of detectable systemic inflammation, a significant increase in IL-10, and with lower mid-term mortality.
Most clinical, laboratory, and instrumental features were matched in the 2 STEMI patient groups, with few exceptions; as expected, IL-6 was higher in older subjects, and an increase in IL-6 was associated with an increase in CRP and a decrease in high-density lipoprotein, which could be explained as part of an inflammatory response. 24 From a previous study, we know that the IL-6 peak in patients with STEMI treated by primary angioplasty occurs after 24 hours from the onset of symptoms and that the peak IL-6 level is ≈5-times higher than at baseline. 11 In the present study, the median ischemic time in patients with IL-6 + IL-10 + STEMI was ≈2.5 hours. This period of time is apparently too short to explain the sharp increase in IL-6, whose levels were ≈9-times higher in IL-6 IL-10 + STEMI groups at the site of injury during myocardial infarction. 25 Yet, the lack of systemic cytokine elevation in IL-6 − IL-10 + STEMI patients indicates that localized inflammation is not sufficient on its own to justify the inflammatory pattern in IL-6 + IL-10 + STEMI patients, at least in the first hours after STEMI onset. It is possible that a homeostatic response mediated by anti-inflammatory signals such as IL-10 and pentraxin 3 could contribute to quenching the systemic proinflammatory signals in IL-6 − IL-10 + STEMI patients. The observation that patients presenting with high levels of IL-6 (in the absence of other causes that may account for such an increase) have substantially worse prognoses suggests that patients with an inflammatory STEMI represent a high-risk population. The data that patients with IL-6 levels above the 70th percentile, ie, IL-6 + STEMI patients, have an increased risk of death have been further supported by results obtained from the independent cohort of Swedish STEMI patients with a longer follow-up time (mean follow-up 3.3±1.3 years). Data from the Swedish STEMI cohort showed that IL-6 + STEMI patients had increased CRP levels compared with IL-6 − STEMI patients, both at 48 hours and at 3 months from the acute event (Online Table V) , suggesting that inflammatory stimuli persist over time and that they can potentially affect the prognosis even months after the acute event. Among potential mechanisms that could explain an increase in fatal outcomes associated with IL-6 + IL-10 + in STEMI patients, we identify the association of IL-6 levels with impaired coronary flow after PCI, in line with previous reports, 27 and with impairment of LV function at discharge.
IL-6 is a sensitive marker of systemic inflammation, and its production is triggered by vastly heterogeneous events. We exploited a novel clustering analysis algorithm 17 and a new strategy to model the problem from a functional module perspective, 15, 16 which allowed us to go beyond the ill-suited and simplistic axiom of a single marker. 23 In fact, this innovative methodology increased the robustness of detecting inflammatory patterns in a dynamic event such as early STEMI. We inferred 2 functional modules using clustering analysis: D1 (composed of IL-10, IL-8, MIP1α, and CRP) and D2 (composed of MCP, MIG, and MIP1β) that were the most effective at discriminating IL-6 + IL-10 + STEMI from IL-6 − IL-10 + STEMI patients and controls. In the module that includes IL-10 and downstream inflammatory signals such as chemokines (IL-8 and MIP1α) and acute-phase proteins such as the short chain pentraxin CRP, IL-10 might be generated to buffer the potentially inflammatory response to IL-6. The D1 and D2 functional modules offered significant predictive values, but they did not improve the ability of IL-6 alone to identify patients at increased risk for mortality. However, combining IL-6, IL-10 (derived from the D1 functional module), and MIG (derived from the D2 functional module) significantly increased the predictive robustness with respect to single cytokine predictive values. This suggests that the combination of orthogonal information filtered (in the sense of being decomposed and selected) 22 by different functional modules could refine our ability to identify patients at increased risk.
We recognized cytokine patterns analyzing a limited number of signals. Most cytokines, including IL-8, IL-10, MCP1, and inducible protein 10, seem to be equally relevant in the study of cardiovascular diseases. 8, 28, 29 It is likely that future studies will allow us to obtain a more comprehensive and detailed account of ongoing molecular interactions in each module and their possible relevance to atherothrombosis, post-STEMI damage, or reperfusion injury.
The cytokine detectable in the blood of STEMI patients could be a contributing event of the acute coronary occlusion or a consequence of still unidentified events during myocardial injury that lead to a diverse inflammatory response, despite similar extent of damage. 25 In the former case, a subclinical and transient infection or an inappropriate immune activation response could modify the cytokine balance in subjects with permissive backgrounds (ie, in the presence of cardiovascular risk factors) and trigger STEMI. [30] [31] [32] [33] The response of endothelial cells infected by Chlamydophila pneumoniae is similar to most features of IL-6 + IL-10 + STEMI patients. 34 Alternatively, the high IL-6 levels reported in a fraction of STEMI patients could indicate a diverse response to myocardial injury. [35] [36] [37] Downregulation of glycoprotein 130-mediated (IL-6 receptor subunit) signal transducer and activator of transcription 3 in an experimental model of myocardial infarction plays an important role in limiting cardiac inflammation and adverse remodeling. 36 IL-10 could play a similar protective response. In experimental models, IL-10 suppresses inflammation and improves LV function and remodeling by suppressing matrix metalloproteinase-9 and thus inhibiting fibrosis. 38 During STEMI, we have previously reported a parallel increase in IL-10 and regulatory T cells. 32 In animal models, IL-6 + IL-10 + and IL-6 − IL-10 + STEMI 1347 regulatory T cells substantially limit postischemic brain damage by targeting multiple inflammatory pathways, and IL-10 is essential to T-cell immunomodulatory effect. 39 Independently of the actual pathophysiological role of IL-6, we found that its increase was associated with a worse 6-month outcome. Interestingly, an increase in IL-10 also was associated with higher mortality at 6 months. 40 The fact that pentraxin 3, despite its known cardioprotective effects, 41, 42 is increased in early STEMI 26 and correlates with poor prognosis 43 might be analogous with IL-10, at least in its control mechanisms.
In conclusion, our results suggest that the inflammatory component associated with STEMI is not relevant in every patient, 13 and that there is extreme variability in the degree of increase in cytokine levels, even in the subgroup of patients with high levels of IL-6. That could be explained by the fact that we are seeking to describe a dynamic process, and in this setting the kinetics of release, distribution, accumulation, and disappearance are not known. Our ML approach is crucial to understanding the reciprocal relationships among cytokines in a complex dynamic process such as myocardial infarction. Clearly, isolated analysis of single cytokines is not appropriate to shed light on these complex mechanisms. Using our computational biology approach, we decorrelated the information delivered by the cytokine/chemokine signals and we inferred 2 active functional modules, which we later exploited to formulate the AC index.
The AC index was the only parameter that demonstrated high predictive robustness both for mortality and for impaired LV function at discharge, outperforming other factors, such as single cytokines and classical prognostic factors, that are associated with mortality, such as age and creatinine level. However, the impact of such a sophisticated bioinformatic approach on practical clinical procedures will be apparent only after the single-biomarker philosophy is dismissed and new combined parameters, such as the AC index, are developed and tested in future clinical studies. We are aware that the example offered here represents a proof-of-concept that needs further validation and extension. Nevertheless, we hope that our methodology provides a means to inspire translational medicine procedures in which new combined parameters, inferred by applying the ML approach to molecular signals, might be proposed for prompt translation and testing in clinical practice.
Finally, considering their relatively homogeneous clinical features at presentation, the characterization of 2 typologies of STEMI patients via diverse early cytokine responses and midterm prognoses could have potential implications for stratification of patients. This could possibly aid in the identification of target subjects for immune-modulating therapies during STEMI (for instance, with cyclosporine A or IL-1β antagonist). 4, 44 In fact, previously adopted strategies that acutely reduced IL-6 levels 11 have been demonstrated to ameliorate the prognosis. 45 
